Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) Equity Average (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Equity Average for 14 consecutive years, with $224.6 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 27.44% to $224.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $224.6 million through Dec 2025, down 27.44% year-over-year, with the annual reading at $248.8 million for FY2025, 36.04% up from the prior year.
  • Equity Average hit $224.6 million in Q4 2025 for Perspective Therapeutics, down from $254.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $334.7 million in Q3 2024 to a low of $40.4 million in Q1 2021.
  • Historically, Equity Average has averaged $149.8 million across 5 years, with a median of $95.3 million in 2023.
  • Biggest five-year swings in Equity Average: surged 1130.96% in 2021 and later decreased 27.44% in 2025.
  • Year by year, Equity Average stood at $65.1 million in 2021, then dropped by 13.68% to $56.2 million in 2022, then surged by 54.84% to $87.0 million in 2023, then soared by 255.93% to $309.6 million in 2024, then dropped by 27.44% to $224.6 million in 2025.
  • Business Quant data shows Equity Average for CATX at $224.6 million in Q4 2025, $254.0 million in Q3 2025, and $275.2 million in Q2 2025.